AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03411473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGEN1884 in combination with pembrolizumab
Description: AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations
Study NCT02093598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study NCT04568590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: If the guardian screens positive for vaccine hesitancy (i.e., vaccine hesitancy score average > 3), they will be given the informational handout along with a brief script.
Study NCT03220217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide trizoxetan 5-20μg
Description: Positron emission tomography (PET) imaging agent
Study NCT03220217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satoreotide trizoxetan 30-45μg
Description: Positron emission tomography (PET) imaging agent
Study NCT00456235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Study NCT01581333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empirical antimicrobial treatment discontinuation
Description: Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.
Study NCT01581333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard empirical antimicrobial treatment discontinuation
Description: The empirical antimicrobial treatment discontinuation will occur when the patient is:~The neutrophil count is above 500 million per mm3.
Study NCT03527329 — intervention group
Intervention type: DEVICE
Intervention: WarmTouch Model 5900, Covidien Ltd, Mansfield, USA
Description: Forced-air warming will be applied following routine clinical practice. The pre-warming time will depend on the time the patient has to wait before entering in the operating room. Prewarming time will be recorded for each patient.
Study NCT02700386 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adjuvant Hypofractionated Radiation
Description: Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.
Study NCT03914326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state
Study NCT03914326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Placebo tablets to be taken with water at the same time every morning in a fasting state
Study NCT01617265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Procedure to Prevent Oversedation
Description: Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
Study NCT01617265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual sedation practice
Description: Sedation and analgesia will be administered according to the usual practices in each participating center.
Study NCT02441517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.
Study NCT01880996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai-chi/Qi-gong
Description: Tai-chi/Qi-gong employs a series of positions and movements that are performed in a slow, flowing manner to help a person concentrate on breathing and motion. The treatments will take place once a week at the Dept. of the Gyneco-oncology and the patients will be instructed to practice tai-chi at home on a daily basis
Study NCT00224952 — intervention group
Intervention type: OTHER
Intervention: No intervention; Urine Collection
Description: Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
Study NCT03571568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-1206
Description: BI-1206 150 mg / 225 mg Subcutaneous injection~BI-1206 50 mg /100 mg Intravenous infusion
Study NCT03571568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2, as per SmPC
Study NCT03571568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib 100 mg orally as per SmPC
Study NCT04746170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Labor Dance
Description: Pregnant women in the experimental group will be given a birth dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm. The massage application will be made by the researcher to their waist and sacrum area with a ball massage glove.
Study NCT01452919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally
Study NCT01452919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2140023
Description: Administered orally
Study NCT01452919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT04085757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: long interval dinoprostone
Description: A small envelope including two labeled plastic bags (A \& B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
Study NCT04085757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: short interval dinoprostone
Description: A small envelope including two labeled plastic bags (A\& B) (each bag containing either 1 dinoprostone tablet(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
Study NCT02915003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-health website
Description: e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
Study NCT01743820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Study NCT01755923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg once per day until the progression disease or intolerant side effects
Study NCT01755923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 iv, d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
Study NCT00670449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod was supplied in capsules.
Study NCT04408716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation Index Guided High-Power Short-Duration Strategy
Description: Point-by-point circumferential pulmonary vein ablation will be performed using the advanced STSF catheter under ablation index guided high power short duration strategy (Radiofrequency energy is set up at a power of 50 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 20 mL/min; Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
Study NCT04408716 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiofrequency Ablation Technique
Description: Point-by-point circumferential pulmonary vein ablation will be performed using the ST catheter under standard radiofrequency ablation settings (Radiofrequency energy is set up at a power of 30 to 35 W, temperature of 43 °C, contact force of 5-20 gram, and flow rate of 17 to 30 mL/min. Target ablation index is set to 500 at the anterior wall and 350 at the posterior wall of left atrium).
Study NCT03230240 — intervention group
Intervention type: DRUG
Intervention: HIPEC
Description: heated intraIP chemotherapy
Study NCT01446835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nelfilcon A contact lens with print
Description: Investigational spherical contact lens
Study NCT01446835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A contact lens with print
Description: Commercially marketed (Singapore) spherical contact lens
Study NCT00468013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Building Exercises
Description: Weekly exercises for 6 weeks
Study NCT00468013 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Journaling
Description: Weekly exercises for 6 weeks
Study NCT03679572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot assisted partial nephrectomy super-selective clamping
Description: The device used to performe the surgery is a Da Vinci robot. After injection of infracyanine, the super-selective clamping is possible. The surgery is performed using a specific clamping of the tumor arteries. Super-selective ischemia is checked using near infrared fluorescence.
Study NCT03679572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot assisted partial nephrectomy with renal artery clamping
Description: Partial nephrectomy is performed with the conventional method in wich a renal artery clamping is done.
Study NCT00800085 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: glucose 20%
Description: maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
Study NCT01967927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MISO
Description: A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
Study NCT01488227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 4000 IU of Vitamin D daily for 6 months
Study NCT01488227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acts as a control for the Vitamin D intervention
Study NCT02698020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Room-air
Description: Provision of room-air
Study NCT04256642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: A nerve block that injects local anesthetic in the Erector Spinae Plane
Study NCT04256642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: Intrathecal morphine at the time of spinal anesthesia
Study NCT04968327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs)
Description: MOPs included shallow perforations of the buccal cortical plate surrounding the tooth that requires orthodontic tooth movement, with no flap reflection was performed using a surgical bur using the special calibrated device called PROPEL
Study NCT04968327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional canine retraction
Description: using nickel-titanium (NiTi) closed coil-springs delivering a force of 150 grams per side
Study NCT04968327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional canine retraction
Description: using nickel-titanium (NiTi) closed coil-springs delivering a force of 150 grams per side
Study NCT04527458 — intervention group
Intervention type: OTHER
Intervention: Patient Characteristics
Description: Characteristics of the patients
Study NCT04527458 — intervention group
Intervention type: OTHER
Intervention: COVID-19 treatments
Description: Specific treatments used on COVID-19 patients
Study NCT04527458 — intervention group
Intervention type: OTHER
Intervention: Differences in triage
Description: Triage criteria for treating COVID-19 patients
Study NCT04527458 — intervention group
Intervention type: OTHER
Intervention: Surge capacity
Description: Capacity of hospitals
Study NCT04579458 — intervention group
Intervention type: PROCEDURE
Intervention: Collection of tears and saliva.
Description: Saliva and ocular tears will be collected.
Study NCT00505765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-108
Description: AL-108, 5 mg/day- one spray in each nostril once per day
Study NCT00505765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-108
Description: AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
Study NCT00505765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- 3 sprays in each nostril, twice per day
Study NCT00505765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- one spray in each nostril, once per day
Study NCT00683852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole 5mg
Description: Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
Study NCT00683852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole 2mg
Description: For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
Study NCT00683852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
Study NCT00683852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
Study NCT02921594 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty with Vanguard XP
Study NCT02921594 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty with Vanguard CR
Study NCT00561795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib (GW786034)
Description: 800 mg orally once a day for 6 cycles
Study NCT00561795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV over one hour every 3 weeks of 6 cycles
Study NCT00561795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV 175 mg/m\^2 given over 3 hours on day one of a 21 day cycle for six cycles
Study NCT03396172 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
Study NCT03396172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeDom
Description: Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation
Study NCT01768182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
Study NCT01768182 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
Study NCT02655497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Study NCT02655497 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial education
Study NCT01743820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin-piperaquine
Study NCT01743820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.125 mg/kg Primaquine
Study NCT01743820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg Primaquine
Study NCT01743820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg Primaquine
Study NCT01743820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.0625 mg/kg Primaquine
Study NCT01058694 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short Message Services to Support ARV therapy adherence
Description: Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
Study NCT01058694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Message Services to Support ARV therapy adherence
Description: Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
Study NCT00003512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT00582998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Dressing
Description: Following repair of fracture of calcaneus, pilon or tibial plateau, a standard wound dressing is applied in the OR. Dressing is taken down post-op day 1 to evaluate draining, and if necessary, replaced. Dressing will be monitored for drainage every 48 hours until wound is clean, dry and intact.
Study NCT00582998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Assisted Closure Device
Description: Following repair of fracture of calcaneus, pilon or tibial plateau, a Vacuum Assisted Closure (VAC) device is applied in the OR. VAC cannister is evaluated for drainage, and if necessary, replaced. VAC sponge will be monitored for drainage every 48 hours, replaced if needed, until wound is clean, dry and intact.
Study NCT00196144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized Programming of PVAB
Description: Performance of a test to detect far-field R-wave sensing
Study NCT00196144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nominal PVAB
Description: nominal pacemaker settings
Study NCT03269058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg daily per os
Study NCT03269058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo of Dapagliflozin per day per os
Study NCT03276546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: shared decision-making tool (SHARE-D)
Description: questionnaire
Study NCT04357808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Single dose treatment with sarilumab 2 x 200 mg subcutaneously
Study NCT04357808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standar of care
Description: Usual clinical care
Study NCT02792153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.
Study NCT00038233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)